Phreesia, Inc. (NYSE:PHR) CEO Sells $77,541.12 in Stock

Phreesia, Inc. (NYSE:PHR) CEO Chaim Indig sold 3,392 shares of the firm’s stock in a transaction dated Monday, April 15th. The stock was sold at an average price of $22.86, for a total value of $77,541.12. Following the transaction, the chief executive officer now directly owns 1,222,005 shares in the company, valued at approximately $27,935,034.30. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Chaim Indig also recently made the following trade(s):

• On Monday, April 8th, Chaim Indig sold 12,043 shares of Phreesia stock. The stock was sold at an average price of $22.62, for a total value of $272,412.66.

Phreesia Price Performance

PHR stock opened at $22.62 on Friday. The firm has a 50 day moving average of $24.40 and a 200-day moving average of $21.26. Phreesia, Inc. has a 12-month low of $12.05 and a 12-month high of $34.98. The company has a current ratio of 1.78, a quick ratio of 1.78 and a debt-to-equity ratio of 0.02.

Phreesia (NYSE:PHR) last posted its quarterly earnings results on Thursday, March 14th. The company reported ($0.56) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.58) by $0.02. Phreesia had a negative net margin of 38.42% and a negative return on equity of 53.33%. The company had revenue of $95.00 million during the quarter, compared to the consensus estimate of $93.52 million. During the same period last year, the firm earned ($0.72) EPS. The company’s revenue for the quarter was up 24.0% on a year-over-year basis. As a group, research analysts expect that Phreesia, Inc. will post -1.48 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on PHR shares. Robert W. Baird raised their price target on Phreesia from $30.00 to $31.00 and gave the stock an “outperform” rating in a report on Monday, March 18th. Canaccord Genuity Group raised their price target on Phreesia from $36.00 to $37.00 and gave the stock a “buy” rating in a report on Friday, March 15th. Truist Financial started coverage on Phreesia in a report on Monday, February 26th. They set a “buy” rating and a $35.00 price target on the stock. Stephens reissued an “overweight” rating and set a $28.00 price target on shares of Phreesia in a report on Friday, March 22nd. Finally, Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $23.00 price objective on shares of Phreesia in a report on Thursday, March 21st. Two investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. Based on data from MarketBeat, Phreesia presently has an average rating of “Moderate Buy” and an average target price of $31.62.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. State of Wyoming raised its holdings in Phreesia by 34.6% in the 2nd quarter. State of Wyoming now owns 1,918 shares of the company’s stock valued at $59,000 after acquiring an additional 493 shares during the last quarter. American International Group Inc. lifted its holdings in Phreesia by 2.3% in the 4th quarter. American International Group Inc. now owns 26,342 shares of the company’s stock worth $610,000 after buying an additional 591 shares in the last quarter. The Manufacturers Life Insurance Company lifted its holdings in Phreesia by 3.6% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 20,545 shares of the company’s stock worth $637,000 after buying an additional 710 shares in the last quarter. Capital Impact Advisors LLC lifted its holdings in Phreesia by 4.2% in the 4th quarter. Capital Impact Advisors LLC now owns 21,262 shares of the company’s stock worth $688,000 after buying an additional 851 shares in the last quarter. Finally, Captrust Financial Advisors lifted its holdings in Phreesia by 154.6% in the 2nd quarter. Captrust Financial Advisors now owns 1,426 shares of the company’s stock worth $36,000 after buying an additional 866 shares in the last quarter. 92.10% of the stock is currently owned by institutional investors and hedge funds.

Phreesia Company Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.